^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

ER positive

i
Other names: ESR1, Era, ESR, NR3A1, ER, ER beta
Entrez ID:
1d
NORDIS: Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma (clinicaltrials.gov)
P=N/A, N=50, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • PGR positive
1d
New trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
1d
Multiple Small Axillary Masses With Haloes on Ultrasound Mimicking Lymph Node Metastases in Breast Cancer: A Case Report. (PubMed, Cureus)
These images and pathological findings suggest that multiple small axillary masses with haloes on ultrasound are not lymph node metastases of breast cancer. Breast specialists, therefore, should develop therapeutic strategies based on the idea that multiple small axillary nodules with haloes on ultrasound have a high probability of in-breast recurrence.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive
3d
KDM5B cooperates with CRL4B complex to promote the tumorigenesis of ER+ breast cancer via regulating cholesterol metabolism. (PubMed, Cell Death Dis)
KDM5B upregulation was significantly negatively correlated with the survival rates in various cancer types, including thyroid, lung, esophageal and colorectal cancers. Overall, these findings establish a novel regulatory axis in cholesterol metabolism, uncover potential therapeutic vulnerabilities in ER+ breast cancer, and suggest that targeting the KDM5B could provide a strategy to curb tumor progression.
Journal
|
ER (Estrogen receptor) • DDB1 (Damage Specific DNA Binding Protein 1) • CUL4B (Cullin 4B) • KDM5B (Lysine Demethylase 5B)
|
ER positive
3d
Citrate silver nanoparticles modulate estrogen signaling in estradiol-supplemented ER-positive breast cancer cells. (PubMed, Mol Cell Endocrinol)
Our results suggest that the surface chemistry of silver nanoparticles may facilitate their ability to modulate estrogen signaling and interact with the estrogen receptor. Furthermore, the nanoplastics pollution may influence the cytotoxicity of silver nanoparticles. This paper highlights the importance of endocrine research in breast cancer, particularly within the context of nanoplastics pollution and the use of nanotechnology in breast cancer treatment.
Journal
|
ER (Estrogen receptor) • CAV1 (Caveolin 1) • GPER1 (G Protein-Coupled Estrogen Receptor 1)
|
ER positive • ER negative
3d
Integrating molecular classification into endometrial cancer management. (PubMed, Eur J Surg Oncol)
We also discussed implementation challenges, including test standardization, reporting, equity of access, and areas of ongoing uncertainty. This position paper aims to support consistent, equitable, and biologically informed management of endometrial carcinoma in contemporary practice.
Review • Journal
|
ER (Estrogen receptor) • MSI (Microsatellite instability)
|
ER positive • MSI-H/dMMR • ER negative
4d
New P2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive
|
letrozole
4d
New P3 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive
|
Oncotype DX Breast Recurrence Score®Test
|
Kisqali (ribociclib) • letrozole • anastrozole • exemestane
4d
Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis. (PubMed, Breast)
Obesity was associated with a modestly higher risk of ER-positive BC, driven by postmenopausal status. Considering potential confounders, in premenopausal women, higher BMI was associated with lower risk of ER-positive BC, and an increased risk of ER-negative BC.
Retrospective data • Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • ER negative
4d
Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial. (PubMed, Cancer Immunol Res)
In addition, post-vaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.
P1 data • Journal
|
ER (Estrogen receptor) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • SCGB2A2 (Secretoglobin Family 2A Member 2)
|
ER positive
|
mammaglobin-A DNA vaccine
5d
Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence (clinicaltrials.gov)
P=N/A, N=305, Completed, Thomas Jefferson University | Active, not recruiting --> Completed
Trial completion
|
ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive
5d
New trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HER-2 negative • HER-2 negative + ER positive
|
EndoPredict®